Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open Label Phase II Study to Evaluate the Efficacy and Safety of Inotuzumab Ozogamicin for Induction Followed by Chemotherapy Consolidation and Maintenance Therapy In Patients Aged 56 Years and Older With Acute Lymphoblastic Leukemia (ALL)

NCT03460522 is registered in ClinicalTrials.gov with Nicola Goekbuget as lead sponsor.

NCT NCT03460522
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03460522 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open Label Phase II Study to Evaluate the Efficacy and Safety of Inotuzumab Ozogamicin for Induction Followed by Chemotherapy Consolidation and Maintenance Therapy In Patients Aged 56 Years and Older With Acute Lymphoblastic Leukemia (ALL)
Lead sponsor
Nicola Goekbuget
Phase
Phase 2
Overall status
Unknown status
Start date
May 2, 2018
Completion date
December 31, 2025
Enrollment
65 (estimated)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

precursor cell lymphoblastic leukemia